Showing results (1291-1300 of 1,538) with videos related to

Sort By:
Pageof 154
Prostate Cancer and Prostatic Diseases|October 3, 2020
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamideNaomi B Haas, Michael J LaRiviere, Thomas H Buckingham, et al.
Epilepsy & Behavior : E&B|November 19, 2015
Risk factors for reading disability in families with rolandic epilepsyYaiza Hernández Vega, Anna Smith, Hannah Cockerill, et al.
Clinical Parkinsonism & Related Disorders|February 9, 2026
CSF tap test parameters and Short-Term outcomes in operated and non-operated patients with idiopathic normal pressure Hydrocephalus: A cohort studySagar Poudel, Deepa Dash, Aparna Wagle Shukla, et al.
Cancer Medicine|March 27, 2025
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and InclusionBenjamin D Mercier, Ameish Govindarajan, Daniela V Castro, et al.
Nature Medicine|March 1, 2022
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trialNazli Dizman, Luis Meza, Paulo Bergerot, et al.
Clinical Genitourinary Cancer|June 10, 2023
Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer ResearchHedyeh Ebrahimi, Daniela V Castro, Matthew I Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell CarcinomaNizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
European Urology|December 18, 2017
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on OutcomesMatthew D Galsky, Huan Wang, Noah M Hahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaT K Choueiri, R J Motzer, B I Rini, et al.
Clinical Genitourinary Cancer|August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry ExperienceBrian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Pageof 154